機関投資家の保有一覧

Rock Springs Capital Management LP

持ち方

やや集中

主力銘柄を持ちつつ裾野も広い持ち方

上位5銘柄の比重

32%

保有

93銘柄

概算評価額 $2.1B

多い業種:ヘルスケア 99%資本財 1%

93銘柄を抱え、首位のRevolution Medicines (RVMD)でも12%。上位にはEli Lilly (LLY)とargenx (ARGX)が並ぶ。上位5銘柄を合わせて32%で、一社に成績を預ける持ち方ではない。資金の99%がヘルスケアに集まり、実質はこの業種そのものへの投資に近い。概算$2.1Bを、この顔ぶれに配っている。

主力の10銘柄

1
RV
RVMDRevolution Medicines
ヘルスケア・ 1,209,465 株
$249M
構成比 12.1%
2
LL
LLYEli Lilly
ヘルスケア・ 98,700 株
$114M
構成比 5.5%
3
AR
ARGXargenx
ヘルスケア・ 98,500 株
$102M
構成比 4.9%
4
TV
TVTXTravere Therapeutics
ヘルスケア・ 1,477,954 株
$98M
構成比 4.8%
5
MD
MDGLMadrigal Pharmaceuticals
ヘルスケア・ 170,999 株
$92M
構成比 4.5%
6
MI
MIRMMirum Pharmaceuticals
ヘルスケア・ 811,294 株
$80M
構成比 3.9%
7
RY
RYTMRhythm Pharmaceuticals
ヘルスケア・ 689,748 株
$73M
構成比 3.6%
8
KY
KYMRKymera Therapeutics
ヘルスケア・ 496,871 株
$59M
構成比 2.9%
9
AS
ASNDAscendis Pharma
ヘルスケア・ 194,000 株
$51M
構成比 2.5%
10
EL
ELVNEnliven Therapeutics
ヘルスケア・ 826,500 株
$48M
構成比 2.3%

残り 83 銘柄をすべて見る ▾

#	銘柄	保有株数	概算評価額
11	XENEXenon Pharmaceuticals	763,020	$46M
12	SRRKScholar Rock Holding	739,816	$42M
13	PENPenumbra	120,500	$39M
14	INSMInsmed	314,300	$38M
15	THCTenet Healthcare	125,000	$33M
16	DXCMDexcom	355,600	$32M
17	IRTCiRhythm Holdings	261,750	$31M
18	ISRGIntuitive Surgical	82,000	$31M
19	RAREUltragenyx Pharmaceutical	1,218,773	$31M
20	GPCRStructure Therapeutics	640,217	$29M
21	HTFLHeartflow	572,500	$29M
22	ACRSAclaris Therapeutics	4,472,650	$27M
23	AGIOAgios Pharmaceuticals	799,163	$27M
24	CLDXCelldex Therapeutics	650,270	$26M
25	BSXBoston Scientific	515,300	$25M
26	DYNDyne Therapeutics	972,198	$25M
27	NBIXNeurocrine Biosciences	150,450	$23M
28	AGLagilon health	260,000	$23M
29	PHVSPharvaris	645,533	$22M
30	COGTCogent Biosciences	624,155	$22M
31	MMEDMiniMed Group	1,055,000	$21M
32	ZLABZai Lab	814,707	$21M
33	UNHUnitedHealth Group	53,000	$21M
34	ERASErasca	1,103,469	$20M
35	AZTAAzenta	569,100	$19M
36	ALNYAlnylam Pharmaceuticals	74,000	$18M
37	MBXMBX Biosciences	287,967	$18M
38	VERAVera Therapeutics	503,585	$17M
39	AMLXAmylyx Pharmaceuticals	499,764	$17M
40	TARSTarsus Pharmaceuticals	225,179	$17M
41	ZBIOZenas BioPharma	502,077	$16M
42	NAMSNewAmsterdam Pharma	588,794	$15M
43	CAICaris Life Sciences	563,000	$14M
44	OMDAOmada Health	541,000	$13M
45	DHRDanaher	61,500	$13M
46	EVHEvolent Health	2,675,000	$12M
47	BCAXBicara Therapeutics	489,095	$11M
48	MLYSMineralys Therapeutics	439,751	$11M
49	PTCTPTC Therapeutics	161,798	$11M
50	BBIOBridgeBio Pharma	128,250	$10M
51	SMMTSummit Therapeutics	710,000	$10M
52	IMNMImmunome	347,666	$10M
53	TNGXTango Therapeutics	386,915	$9M
54	ARDXArdelyx	2,299,473	$9M
55	ALKSAlkermes	183,986	$9M
56	INSPInspire Medical Systems	131,800	$8M
57	REGNRegeneron Pharmaceuticals	10,100	$8M
58	CMPXCompass Therapeutics	3,305,308	$8M
59	PHRPhreesia	600,400	$7M
60	INDVIndivior Pharmaceuticals	200,000	$7M
61	JANXJanux Therapeutics	367,009	$7M
62	TMOThermo Fisher Scientific	10,000	$6M
63	FOCLEDAP TMS	1,378,000	$6M
64	CORTCorcept Therapeutics	50,250	$6M
65	RCUSArcus Biosciences	180,000	$5M
66	SYKStryker	14,800	$5M
67	TLPHTalphera	3,589,186	$4M
68	NVONovo Nordisk	90,000	$4M
69	OCULOcular Therapeutix	383,716	$4M
70	NGNENeurogene	104,339	$4M
71	CVSCVS Health	40,000	$4M
72	PCVXVaxcyte	60,250	$4M
73	ROIVRoivant Sciences	97,000	$3M
74	ATECAlphatec Holdings	350,000	$3M
75	CYTKCytokinetics	45,364	$3M
76	VKTXViking Therapeutics	96,000	$3M
77	SGRYSurgery Partners	208,000	$3M
78	DNTHDianthus Therapeutics	26,757	$3M
79	IPSCCentury Therapeutics	1,304,347	$3M
80	EWEdwards Lifesciences	28,900	$3M
81	ACHCAcadia Healthcare	75,500	$2M
82	OLMAOlema Pharmaceuticals	170,378	$2M
83	TEVATeva Pharmaceutical	45,500	$2M
84	JAZZJazz Pharmaceuticals	5,750	$1M
85	LENZLENZ Therapeutics	257,460	$1M
86	EYPTEyePoint Pharmaceuticals	258,739	$1M
87	MLTXMoonLake Immunotherapeutics	61,700	$929K
88	LEGNLegend Biotech	40,500	$842K
89	JSPRJasper Therapeutics	1,100,726	$782K
90	SIONSionna Therapeutics	99,429	$600K
91	ORKAOruka Therapeutics	4,123	$382K
92	GOSSGossamer Bio	1,609,492	$274K
93	BCRXBioCryst Pharmaceuticals	12,600	$122K

2026年3月31日時点の SEC への Form 13F 届出 (運用資産 $100M 以上の機関投資家が四半期ごとに提出) の集計。届出は四半期末から最大45日遅れで公開されるため、現在の保有と異なる場合があります。概算評価額と構成比は当サイトの株価で計算した参考値です。届出対象外の資産 (米国外上場株・債券など) は含まれません。

銘柄一覧に戻る